Concurrent gonadotropin-releasing hormone agonist administration with chemotherapy improves neoadjuvant chemotherapy responses in young premenopausal breast cancer patients

Journal of Breast Cancer

Volumn 18, Issue 4, 2015, Pages 365-370

  Kim, Hee Jeong ^a   Yoon, Tae In ^a   Chae, Hee Dong ^a   Kim, Jeong Eun ^a   Chae, Eun Young ^a   Yu, Jong Han ^a   Sohn, Guiyun ^a   Ko, Beom Seok ^a   Lee, Jong Won ^a   Son, Byung Ho ^a   Ahn, Sei Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Drug therapy; Gonadotropin releasing hormone agonist

Indexed keywords

GOSERELIN; HORMONE RECEPTOR; KI 67 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; DRUG EFFICACY; DRUG RESPONSE; ECHOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

EID: 84957702756     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2015.18.4.365     Document Type: Article

References (13)

1. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-41.
2. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross- King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
3. Blumenfeld Z. ZORO study: discrepancy between the conclusion and the results. J Clin Oncol 2011;29:3340.
4. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32.
5. Kim J, Kim M, Lee JH, Lee H, Lee SK, Bae SY, et al. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy? Breast 2014;23:670-5.
6. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8.
7. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374: 2055-63.
8. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 2009;35:789-96.
9. Schubert A, Hawighorst T, Emons G, Grundker C. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Breast Cancer Res Treat 2011;130: 783-90.
10. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
11. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. Partridge AH. Fertility preservation: a vital survivorship issue for young women with breast cancer. J Clin Oncol 2008;26:2612-3.